• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Voorheis steps down at Advanced NMR

Article

William Voorheis of Advanced NMR has become the latest chief executive to leave a medical imagingcompany after posting 1994 annual results. Advanced NMR announcedthis month that Voorheis is vacating his positions as presidentand COO of the Wilmington,

William Voorheis of Advanced NMR has become the latest chief executive to leave a medical imagingcompany after posting 1994 annual results. Advanced NMR announcedthis month that Voorheis is vacating his positions as presidentand COO of the Wilmington, MA, firm. He will continue to workwith the company in a consulting capacity and remains a directorof Advanced NMR and its subsidiary, Advanced Mammography Systems.

The announcement came 10 days after Advanced NMR posted 1994numbers that saw its revenues increase 173% and its net loss drop42% (SCAN 4/12/95). Voorheis is the third medical imaging executivein the past two months to have lost his job within weeks of releasing1994 results, following Alan Margulis of MMI Medical and DavidRose of OEC Medical Systems (SCAN 3/29/95 and 3/1/95).

An Advanced NMR spokesperson said Voorheis had done an "excellent"job at the firm, but the company felt it needed new blood to moveon to the next level of sales and production. Advanced NMR marketsthe InstaScan echo-planar imaging package and its Advanced MammographySystems subsidiary is developing the Aurora dedicated MR mammographyscanner.

Advanced NMR chairman and CEO Jack Nelson has been appointedacting president of both Advanced NMR and Advanced MammographySystems. Vice president of sales and marketing Robert Kwolyk hasassumed Voorheis' COO duties.

In other Advanced NMR news, the company said that in conjunctionwith Advanced Mammography Systems it has developed a new MR mammographyfat-suppression technique to distinguish tumor from normal fattybreast tissue. The method reduces breast imaging times to undersix minutes, according to the company.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.